




English version



Versión español



CrossMark



OPEN ACCESS

Citation: Correction: Adherence with hormonal therapy in women with breast cancer: a cross-sectional study in Medellín, Colombia. Colomb Méd (Cali), 2025; 56(3):e9007103 <http://doi.org/10.25100/cm.v56i3.7103>

Copyright: © 2025 Universidad del Valle



CORRECTION

Correction: Adherence with hormonal therapy in women with breast cancer: a cross-sectional study in Medellín, Colombia

Corrección: Adherencia a la terapia hormonal en mujeres con cáncer de mama: un estudio transversal en Medellín, Colombia

Correction associated to article: <https://colombiamedica.univalle.edu.co/index.php/comedica/article/view/2025-06-16>

After the publication, the original author of the measurement scale used in the study, Dr. Marty Morisky, has requested that it is necessary to include additional references, a section of acknowledgments with his author details, and to include the score in the definition of adherence levels, as is required for the proper use of the scale.

In compliance with the request, the paragraph stating:

“The dependent variable was adherence to hormonal therapy. The 8-item Morisky Medication Adherence Scale (MMAS-8) is used to assess adherence to treatment. It was administered via telephone to identify behaviors or barriers that interfered with adherence. Based on the score obtained, patients were categorized into high, medium, and low adherence levels (5). For this study, these levels were defined as follows:”

Following the modification, the paragraph is presented as follows:

“The dependent variable was adherence to hormonal therapy. The 8-item Morisky Medication Adherence Scale (MMAS-8) (5-8) is used to assess adherence to treatment. It was administered via telephone to identify behaviors or barriers that interfered with adherence. Based on the score obtained (ranging from 0 to 8), patients were categorized into high (score of 8), medium (scores of ≥ 6 y < 8), and low (scores of < 6) adherence levels. For this study, these levels were defined as follows:”

Additionally, the acknowledgment statement has been added, as it was not included in the original article:

Acknowledgment

The MMAS-8 Scale, content, name, and trademarks are protected by US copyright and trademark laws. Permission for use of the scale and its coding is required. A license agreement is available from MMAR, LLC., www.moriskyscale.com

Additional references were incorporated to support the use of MMAS-8 Scale

1. Berlowitz DR, Foy CG, Kazis LE, Bolin L, Lonroy LB, Fitzpatrick P, et al. for the SPRINT Study Research Group. Impact of intensive blood pressure therapy on patient-reported outcomes outcomes results from the SPRINT study. *N Engl J Med.* 2017; 377:733-44. doi: 10.1056/NEJMoa1611179.
2. Bress AP, Bellows BK, King JB, Hess R, Beddhu S, Zhang Z, et al. for the SPRINT Research Group and the SPRINT Economics and Health Related Quality of Life Subcommittee. Cost-effectiveness of intensive versus standard blood pressure control. *N Engl J Med.* 2017; 377: 745-55. doi: 10.1056/NEJMsa1616035.
3. Adherence. The MMAS-8 Scale, content, name, and trademarks are protected by US copyright and trademark laws. Permission for use of the scale and its coding is required. A license agreement is available from MMAR, LLC. Available from: www.moriskyscale.com.